Study details
Enrolling now
Cardiovascular Effects of Angiotensin-(1-7) in Obesity Hypertension
Milton S. Hershey Medical Center
NCT IDNCT06482853ClinicalTrials.gov data as of Apr 2026
Phase
EARLY_PHASE1
Target enrollment
52
Study length
about 4.2 years
Ages
18–65
Locations
1 site in PA
About this study
Researchers are testing a treatment called angiotensin-(1-7) to see if it can improve cardiovascular health in people with obesity and high blood pressure. The trial will last for 1528 days, and the goal is to enroll 52 participants.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take Angiotensin-(1-7)
- 2.Take Saline
PhaseEARLY_Phase 1
DrugAngiotensin-(1-7)
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low11%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Drug classes
angiotensin II
Endpoints
Secondary: Change in Diastolic Blood Pressure, Change in Heart Rate, Change in Systolic Blood Pressure
Body systems
Endocrinology, Cardiology / Heart